Solomon, B.J. et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 371, 2167–2177 (2014).
Shaw, A.T. et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N. Engl. J. Med. 370, 1189–1197 (2014).
Camidge, D.R. & Doebele, R.C. Treating ALK-positive lung cancer—early successes and future challenges. Nat. Rev. Clin. Oncol. 9, 268–277 (2012).
Shaw, A.T. et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 368, 2385–2394 (2013).
Robert, C. et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med. 372, 30–39 (2015).
Chapman, P.B., Solit, D.B. & Rosen, N. Combination of RAF and MEK inhibition for the treatment of BRAF-mutated melanoma: feedback is not encouraged. Cancer Cell 26, 603–604 (2014).
Johnson, D.B. et al. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600E-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J. Clin. Oncol. 32, 3697–3704 (2014).
Flaherty, K.T. et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694–1703 (2012).
Long, G.V. et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N. Engl. J. Med. 371, 1877–1888 (2014).
Lemmon, M.A. & Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 141, 1117–1134 (2010).
The Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543–550 (2014).
Lovly, C.M. et al. Rationale for co-targeting IGF-1R and ALK in ALK fusion- positive lung cancer. Nat. Med. 20, 1027–1034 (2014).
Alessandrini, A. et al. Mek1 phosphorylation site mutants activate Raf-1 in NIH 3T3 cells. J. Biol. Chem. 271, 31612–31618 (1996).
Takezawa, K. et al. Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer. Clin. Cancer Res. 17, 2140–2148 (2011).
Hainsworth, J.D. et al. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J. Thorac. Oncol. 5, 1630–1636 (2010).
Bivona, T.G. et al. Phospholipase Cγ activates Ras on the Golgi apparatus by means of RasGRP1. Nature 424, 694–698 (2003).
Grabocka, E. et al. Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response. Cancer Cell 25, 243–256 (2014).
Hancock, J.F. Ras proteins: different signals from different locations. Nat. Rev. Mol. Cell Biol. 4, 373–384 (2004).
Bivona, T.G. & Philips, M.R. Ras pathway signaling on endomembranes. Curr. Opin. Cell Biol. 15, 136–142 (2003).
Mano, H. ALKoma: a cancer subtype with a shared target. Cancer Discov. 2, 495–502 (2012).
Shaw, A.T. & Solomon, B. Targeting anaplastic lymphoma kinase in lung cancer. Clin. Cancer Res. 17, 2081–2086 (2011).
Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in non- small-cell lung cancer. Nature 448, 561–566 (2007).
Richards, M.W. et al. Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical B-propeller domain. Proc. Natl. Acad. Sci. USA 111, 5195–5200 (2014).
Pollmann, M. et al. Human EML4, a novel member of the EMAP family, is essential for microtubule formation. Exp. Cell Res. 312, 3241–3251 (2006).
Choi, Y.L. et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res. 68, 4971–4976 (2008).
Shimizu, T. et al. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin. Cancer Res. 18, 2316–2325 (2012).
Zhao, Y.S. & Adjei, A.A. The clinical development of MEK inhibitors. Nat Rev Clin Oncol. 11, 385–400 (2014).
Katayama, R. et al. Mechanisms of acquired crizotinib resistance in ALK- rearranged lung cancers. Sci. Transl. Med. 4, 120ra117 (2012).
Pfister, S. et al. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J. Clin. Invest. 118, 1739–1749 (2008).
Graham, J.M. Jr. et al. Genomic duplication of PTPN11 is an uncommon cause of Noonan syndrome. Am. J. Med. Genet. 149A, 2122–2128 (2009).
Caunt, C.J. & Keyse, S.M. Dual-specificity MAP kinase phosphatase (MKPs): shaping the outcome of MAP kinase signaling. FEBS J. 280, 489–504 (2013).
Ercan, D. et al. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov. 2, 934–947 (2012).
Wilson, T.R. et al. Widespread potential for growth factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505–509 (2012).
Huang, S. et al. MED12 controls the response to multiple cancer drugs through regulation of TGF-B signaling. Cell 151, 937–950 (2012).
Crystal, A.S. et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 346, 1480–1486 (2014).
Nissan, M.H. et al. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res. 74, 430–2350 (2014).
Esfahani, K., Agulnik, J.S. & Cohen, V. A systemic review of resistance mechanisms and ongoing clinical trials in ALK-rearranged non-small cell lung cancer. Front Oncol. 4, 174 (2014).
Doebele, R.C. et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res. 18, 1472–1482 (2012).
Wilson, F.H. et al. A Functional landscape of resistance to ALK inhibition in lung cancer. Cancer Cell 27, 397–408 (2015).
Tanizaki, J. et al. Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells. Br. J. Cancer 106, 763–767 (2012).
Lin, L. et al. Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proc. Natl. Acad. Sci. USA 111, E748–E757 (2014).
Camidge, D.R. et al. Optimizing the detection of lung cancer patients harboring anaplastice lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin. Cancer Res. 16, 5581–5590 (2010).